NOD2
MOLECULAR TARGETnucleotide binding oligomerization domain containing 2
NOD2 (nucleotide binding oligomerization domain containing 2) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NOD2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | paclitaxel | 7.17 | 1301 |
| 2 | pd 0166285 | 2.83 | 16 |
| 3 | Oxyphenbutazone | 1.39 | 3 |
| 4 | Anisomycin | 1.10 | 2 |
| 5 | Digoxin | 1.10 | 2 |
| 6 | Camptothecin | 0.69 | 1 |
| 7 | cycloheximide | 0.69 | 1 |
| 8 | Digitoxin | 0.69 | 1 |
| 9 | Ouabain | 0.69 | 1 |
About NOD2 as a Drug Target
NOD2 (nucleotide binding oligomerization domain containing 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented NOD2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NOD2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.